| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
Dominic Piscitelli is Chief Financial Officer at ORIC, with reported holdings spanning 2 companies. Dominic Piscitelli's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $670K at current prices.
Our model assigns Dominic Piscitelli a middling insider score of 64/100, based on 15 past trades. Over a 12-month horizon, 84.6% of those trades were profitable, with an average 12-month return of +3.5%.
Dominic Piscitelli's largest disclosed position is in ORIC as Chief Financial Officer, worth about $670K. The ORIC filings lean toward selling, a net 194,942 shares.
Dominic Piscitelli has 28 Form 4 filings on record from February 2017 to October 2026, across 2 companies: Chief Financial Officer at ORIC Pharmaceuticals (ORIC), 2020–2026; Chief Financial Officer at Anaptysbio (ANAB), 2017–2019.
The 63 reported transactions were 27 open-market sales, 19 option or other derivative awards, 12 option exercises and 4 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $322K and 16 sales worth about $5.8M.
The only open-market purchase was 60,000 shares of ORIC at an average $5.36 on March 31, 2022, about $322K. Twelve months later ORIC was up 7%.
The largest open-market sale was 37,000 shares of ANAB at an average $72.14 on December 3, 2018, about $2.7M.
11 of the 14 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 3 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2026 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 14,000 | $13.53 | $189,390.60 | -16.7% | - | - | |
| Sep 28, 2026 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 13,400 | $13.53 | $181,257.78 | -16.1% | - | - | |
| Sep 24, 2026 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 600 | $13.50 | $8,102.50 | -0.9% | - | - | |
| Aug 26, 2026 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 77,000 | $13.69 | $1,053,814.30 | -52.4% | - | - | |
| Feb 24, 2026 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 52,000 | $13.51 | $702,686.40 | -43.3% | -36.5% | - | |
| Dec 16, 2025 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE | 10,720 | $9.06 | $97,127.49 | -13.6% | +34.0% | - | |
| Oct 6, 2025 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 11,000 | $14.52 | $159,718.90 | -18.5% | -43.4% | -16.9% | |
| Jul 1, 2025 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sell10b5-1 | 20,000 | $10.05 | $200,972.00 | -29.3% | +14.6% | -6.0% | |
| Jun 24, 2025 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sell10b5-1 | 33,500 | $10.49 | $351,383.60 | -32.9% | +3.1% | -10.1% | |
| Jun 12, 2025 | ORIC Oric Pharmaceuticals, Inc. | Chief Financial Officer | Sell10b5-1 | 300 | $10.00 | $3,000.00 | -0.3% | +8.8% | -14.5% |